OmiCure uses RNA data. This approach was tested and validated through the WINTHER clinical trial. The results of this trial were published in Nature Medicine in April 2019.
Here is a brief summary of the trial.
For the first time in a clinical setting, the WINTHER trial applied transcriptomics (gene expression) to guide decision. Using transcriptional analysis that specifically compared tumor to matched normal tissue, the trial was able to bring personalized cancer treatments to a greater number of patients.
There are now numerous approved drugs affecting molecular pathways frequently aberrant in tumors, and hundreds of novel targeted drugs, including immune-checkpoint modulators, in clinical development. Not unexpectedly, meta-analyses demonstrate that biomarker-driven trials have better outcome than trials lacking biomarkers. Some of the most rapid advances have been achieved with investigation of DNA structural abnormalities.
Unfortunately, not all patients’ tumors have pharmacologically tractable DNA alterations. Thus, extending the application of precision medicine requires a deeper understanding of cancer biology.
Hence, we initiated an international trial WINTHER that prospectively navigated patients to therapy according to either DNA-guided next-generation sequencing (NGS) or transcriptional (RNA) analysis that specifically compared tumor to matched normal tissue.
The WINTHER trial navigated patients to therapy on the basis of fresh biopsy DNA sequencing (arm A; 236 gene panel provided by Foundation Medicine) or RNA expression (arm B; comparing tumor to normal). The most common diagnoses were colon, head and neck, and lung cancers.
“The strategy employed in WINTHER resulted in a higher proportion of patients treated than in many precision medicine trials. Previous studies have identified potential treatments for between 5% and 25 % of patients based on DNA profiling alone, our findings represent an important step toward delivering on the true promise of precision medicine in oncology.”
We were able to observe exceptional responses to gene-targeted therapy according to an RNA match: